Advances in Management of Stable Coronary Artery Disease: the Role of Revascularization?

被引：7

作者：

Voudris K.V. ^{[1
]}

Kavinsky C.J. ^{[1
]}

机构：

[1] Division of Cardiology, Department of Medicine, Rush University Medical Center, 1717 West Congress Parkway, Suite 307, Kellogg Building, Chicago, 60612, IL

来源：

Current Treatment Options in Cardiovascular Medicine | 2019年 / 21卷 / 3期

关键词：

Coronary artery bypass graft; Ischemic heart disease; Percutaneous coronary intervention; Revascularization; Stable coronary artery disease;

D O I：

10.1007/s11936-019-0720-9

中图分类号：

学科分类号：

摘要：

Purpose of review: Coronary artery disease remains the most common cause of death worldwide. In patients with biomarker-positive acute coronary syndrome, the combination of guideline-directed medical therapy with routine revascularization is associated with improved outcomes. However, the role of routine revascularization in stable ischemic heart disease, in addition to medical therapy, remains a matter of debate. In this review, we aimed to describe the role of revascularization in stable ischemic heart disease. Recent findings: Revascularization is indicated in patients with stable ischemic heart disease and progressive or refractory symptoms, despite medical management. When guided by ischemia presence, revascularization has failed to show survival benefit, compared with medical therapy alone in multiple clinical trials. On the other hand, revascularization guided by coronary lesion severity, assessed by FFR or iFR, has been shown to offer survival benefit and improvement in symptom severity. PCI-revascularization of unprotected left main disease is feasible with comparable to surgical approach outcomes. Summary: Clinical decision to perform revascularization in stable ischemic heart disease necessitates a heart team approach, and no simple algorithm can guide this process. Further studies are required to assess the benefit of routine revascularization, in combination to medical therapy, in this population. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.

引用

共 46 条

[1]

Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 9859, pp. 2095-2128, (2012)

[2]

Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., de Ferranti S.D., Floyd J., Fornage M., Gillespie C., Isasi C.R., Jimenez M.C., Jordan L.C., Judd S.E., Lackland D., Lichtman J.H., Lisabeth L., Liu S., Longenecker C.T., Mackey R.H., Matsushita K., Mozaffarian D., Mussolino M.E., Nasir K., Neumar R.W., Palaniappan L., Pandey D.K., Thiagarajan R.R., Reeves M.J., Ritchey M., Rodriguez C.J., Roth G.A., Rosamond W.D., Sasson C., Towfighi A., Tsao C.W., Turner M.B., Virani S.S.,

[3]

Ford E.S., Ajani U.A., Croft J.B., Critchley J.A., Labarthe D.R., Kottke T.E., Giles W.H., Capewell S., Explaining the decrease in U.S. deaths from coronary disease, 1980-2000, N Engl J Med, 356, 23, pp. 2388-2398, (2007)

[4]

Bangalore S., Gupta N., Genereux P., Guo Y., Pancholy S., Feit F., Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials: insight from over 8.1 million percutaneous coronary interventions, Int J Cardiol, 183, pp. 6-10, (2015)

[5]

Keeley E.C., Boura J.A., Grines C.L., Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials, Lancet, 361, 9351, pp. 13-20, (2003)

[6]

Mehta S.R., Cannon C.P., Fox K.A., Wallentin L., Boden W.E., Spacek R., Et al., Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials, JAMA, 293, 23, pp. 2908-2917, (2005)

[7]

Fox K.A., Clayton T.C., Damman P., Pocock S.J., de Winter R.J., Tijssen J.G., Lagerqvist B., Wallentin L., Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data, J Am Coll Cardiol, 55, 22, pp. 2435-2445, (2010)

[8]

Caruba T., Katsahian S., Schramm C., Charles Nelson A., Durieux P., Begue D., Et al., Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies, PLoS One, 9, 6, (2014)

[9]

Katritsis D.G., Ioannidis J.P., Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis, Circulation, 111, 22, pp. 2906-2912, (2005)

[10]

Fihn S.D., Blankenship J.C., Alexander K.P., Bittl J.A., Byrne J.G., Fletcher B.J., Et al., ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease, A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and

← 1 2 3 4 5 →